Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...
About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 pivotal clinical trial evaluating IO102-IO103 in ...
This investigator-initiated, single-arm, open-label, phase 2 study evaluates the efficacy and safety of a triple combination regimen of pembrolizumab plus plinabulin/docetaxel. The study intends to ...
The Company has completed enrollment in the third of five cohorts in the Phase 1 open-label, dose-escalation trial. In this ...
Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.
How have -- I know you just set up the payer team, but how have initial payer discussions been going for pembrolizumab and SMA ... Do not expect that we will have two doses in the label given the ...
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®â–¼ (erdafitinib) as a monotherapy for the treatment ...
TROPION-Lung01 is a global, randomised, multicentre, open-label Phase III trial evaluating the efficacy ... Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated ...
Extending Alecensa's label to include early-stage disease ... blessing to NHS use of MSD's $25 billion immunotherapy Keytruda (pembrolizumab) alongside chemotherapy before surgery for stage ...
More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback